NEW YORK, NY / ACCESSWIRE / September 4, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Realogy Holdings Corp. (RLGY)
Class Period: February 24, 2017 to May 22, 2019
Lead Plaintiff Deadline: September 9, 2019
The complaint alleges that during the class period Realogy Holdings Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) Realogy was engaged in anticompetitive behavior by requiring property sellers to pay the commissions of a buyer’s broker at an inflated rate; (2) Realogy’s anticompetitive actions would prompt the U.S. Department of Justice (“DOJ”) to open an antitrust investigation into the real estate industry’s practices regarding brokers’ commissions; and (3) as a result, Defendants’ statements about the Realogy’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Learn about your recoverable losses in RLGY: http://www.kleinstocklaw.com/pslra-1/realogy-holdings-corp-loss-submission-form?id=3339&from=1
Omnicell, Inc. (OMCL)
Class Period: October 25, 2018 to July 11, 2019
Lead Plaintiff Deadline: September 16, 2019
During the class period, Omnicell, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) as a result, the Company would be required to write-off certain inventory; (5) the Company misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in OMCL: http://www.kleinstocklaw.com/pslra-1/omnicell-inc-loss-submission-form?id=3339&from=1
Sarepta Therapeutics, Inc. (SRPT)
Class Period: September 6, 2017 to August 19, 2019
Lead Plaintiff Deadline: October 29, 2019
The lawsuit alleges Sarepta Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in SRPT: http://www.kleinstocklaw.com/pslra-1/sarepta-therapeutics-inc-loss-submission-form?id=3339&from=1
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on accesswire.com: